fashion -WSS

fashion

author：comprehensive 2025-10-02 01:15:44 - browse：5

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Judge sides with young activists in first

WSS

Gene editing the human germline: What are the risks?

Methadone treatment changes are coming. Do they go far enough?

Mark Cuban is blaming the wrong people for high drug costs

Illumina slashes 2023 revenue projections yet again

Biogen’s boardroom scandal saddles CEO with first crisis

Idaho college killings prosecutors challenge defense's grand jury claims

hotspot

fashion

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

Health AI adoption puts security, privacy startups on investors' radar

BioMarin wins approval for gene therapy to treat hemophilia A

Mark Cuban is blaming the wrong people for high drug costs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Be careful with at

Bright Health sells Medicare Advantage business to Molina

Intermittent fasting comes with a heart risk? Not so fast

Bright Health sells Medicare Advantage business to Molina

Health AI adoption puts security, privacy startups on investors' radar

focus

Illinois Supreme Court finds assault weapons ban constitutional

Baby aspirin cuts fat buildup in liver disease patients, in small study

Hospitals are dialing back on venture capital investing

Baby aspirin cuts fat buildup in liver disease patients, in small study

Bird flu researchers hone in on Finland’s mink farms

Schizophrenia gene found to be linked to cells' energy dysfunction

focus

entertainment

hotspot

explore